All > Heart Attack

PEP in Acute Myocardial Infarction for Heart Attack

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Heart AttackPEP in Acute Myocardial Infarction - Drug
Eligibility
21 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the safety of a new drug for people who have had a heart attack.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Patients with Recent Myocardial Infarction
1
CardiolRx
1
Hemorrhagic Myocardial Infarction - Deferiprone

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Day 1 (Baseline/Screening) visit, Day 40 and Day 365

Day 365
Alloimmune Response
Day 365
Abdominal abnormalities
Day 40
Ejection fraction
Infarction scar size
Day 1
Obstetric Delivery

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Patients with Recent Myocardial Infarction
2
CardiolRx
1
Hemorrhagic Myocardial Infarction - Deferiprone

Trial Design

1 Treatment Group

PEP in Acute Myocardial Infarction
1 of 1

Experimental Treatment

23 Total Participants · 1 Treatment Group

Primary Treatment: PEP in Acute Myocardial Infarction · No Placebo Group · Phase 1

PEP in Acute Myocardial Infarction
Drug
Experimental Group · 1 Intervention: PEP in Acute Myocardial Infarction · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 (baseline/screening) visit, day 40 and day 365

Who is running the clinical trial?

Christopher J. McLeodLead Sponsor
Rion LLCUNKNOWN
1 Previous Clinical Trials
24 Total Patients Enrolled
Guy S Reeder, MDPrincipal InvestigatorMayo Clinic

Eligibility Criteria

Age 21 - 85 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You live within 90 miles of the study site.
You are aged 21-85 years.
You have a recent acute myocardial infarction (heart attack).
You have a QRS complex of ≥2 mm (0.2 mV) in men or ≥1.5 mm (0.
Angiographic evidence of TIMI 0 or TIMI 1 flow through culprit lesion prior to stent placement.
You have angiographic evidence of residual stenosis visually <30% after stent placement.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top